S-1: Lucy Scientific Discovery Files for Resale of Up to 7.36 Million Common Shares

Lucy Scientific Discovery has filed a registration statement for the potential resale of up to 7,361,688 common shares by selling stockholders.

Summary

• Lucy Scientific Discovery Inc. has filed a Form S-1 registration statement with the SEC to allow selling stockholders to resell up to 7,361,688 common shares.
• These shares include 4,497,363 shares issuable upon conversion of senior secured convertible promissory notes, 1,500,000 shares issuable upon exercise of warrants at $0.25 per share, and 1,364,325 shares issuable upon the effectiveness of the registration statement.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders, except potentially from the cash exercise of the warrants, which could result in gross proceeds of approximately $375,000.
• The selling stockholders may sell the shares from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or other means described in the prospectus.
• The last reported sale price for Lucy Scientific Discovery Inc.'s common shares on Nasdaq on January 11, 2024, was $0.2225 per share.
• The company has entered into agreements to acquire the intellectual property of High Times and Bluesky Biologicals Inc., issuing common shares representing 19.9% of the company's total outstanding shares in each transaction, plus potential earn-out payments.
• The company received a deficiency letter from Nasdaq for not maintaining a minimum bid price of $1.00 per share and has until March 19, 2024, to regain compliance.
• The company has a limited operating history and has incurred operating losses since inception, with an accumulated deficit of $46.4 million as of September 30, 2023.
• The company is dependent on raising additional funds and may need to reduce operations if funding is not available.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are potential positives such as the acquisition of new assets and potential revenue from warrant exercises, the company faces significant financial challenges, including an accumulated deficit, concerns about its ability to continue as a going concern, and the need to regain compliance with Nasdaq listing requirements. The overall sentiment is cautiously negative.

Positives

• Potential for $375,000 in gross proceeds if all warrants are exercised for cash.
• Acquisition of High Times intellectual property and Bluesky Biologicals Inc. could expand the company's market presence.
• The company's strategic investment agreement with Hightimes provides $833,333 of annual advertising and marketing credits for five years.
• The company launched new product lines, Mindful by Lucy and Twilight by Lucy, expanding its offerings in the psychoactive alternatives market.

Negatives

• The company will not receive proceeds from the sale of shares by selling stockholders, except potentially from warrant exercises.
• The company has a significant accumulated deficit of $46.4 million.
• The company needs to regain compliance with Nasdaq's minimum bid price requirement by March 19, 2024.
• The company has a limited operating history and has incurred operating losses since inception.
• The company is dependent on raising additional funds and may need to reduce operations if funding is not available.

Risks

• The company's independent auditors have raised concerns about its ability to continue as a going concern.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting.
• The growth of the business depends on completing the acquisitions of Bluesky and the intellectual property of Hightimes, which are subject to approvals.
• Future capital raises may dilute existing stockholders' ownership.
• The company may experience extreme stock price volatility unrelated to its actual or expected operating performance.
• The company has a material weakness in its internal control over financial reporting.
• The company may be subject to claims by third parties asserting that its employees or it have misappropriated their intellectual property, or claiming ownership of what it regards as its own intellectual property.
• The company may be adversely affected by fluctuations in the U.S. dollar relative to the Canadian dollar.

Future Outlook

The company expects to realize significant growth in its business if it is able to complete the acquisition of Bluesky and acquisition of the intellectual property of Hightimes.

Industry Context

The company is operating in the emerging psychedelics and psychoactive alternatives market, which Forbes predicts will double to over $5 billion in gross sales by 2025.

Management Changes

Related Party Transactions

• Paul Abramowitz, one of the company's directors, is a shareholder of Hightimes and is the stepfather of the person who was Executive Chairman of Hightimes through September 2023.
• Mr. Abramowitz's biological son is a beneficial owner of Whistling Pines LLC, one of the Selling Stockholders.

Stakeholder Impact

• Existing shareholders may experience dilution from future equity issuances.
• The company's ability to continue as a going concern is uncertain, which could impact stakeholders.
• The company's stock price may be volatile, which could impact investors.

Next Steps

• The company needs to regain compliance with Nasdaq's minimum bid price requirement by March 19, 2024.
• The company is seeking to complete the acquisitions of Bluesky and the intellectual property of Hightimes.
• The company intends to monitor the psychedelic marketplace and revisit the Dealer License when the regulatory landscape provides for a clearer path to meaningful revenues.

Key Dates

Keywords

common shares, selling stockholders, registration statement, convertible notes, warrants, lucy scientific discovery, acquisition, nasdaq, compliance, financials